Information Provided By:
Fly News Breaks for March 26, 2018
EW, BSX
Mar 26, 2018 | 09:10 EDT
Wells Fargo analyst Lawrence Biegelsen notes USPTO has determined that all claims of the '608 patent that have been asserted against Edwards Lifesciences (EW) are invalid, which the analyst sees as an important victory for the company because the '608 patent is one of Boston Scientific's (BSX) key transcatheter valve patents. While Boston Scientific will appeal the USPTO's decision on the '608 patent, Biegelsen's patent consultant believes the company's chances of overturning the decision are very low.
News For BSX;EW From the Last 2 Days
There are no results for your query BSX;EW
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.